Medicines Patent Pool and ViiV Healthcare collaborate to treat pediatric HIV

28 February 2013

The Medicines Patent Pool (MPP) this week announced the launch of a new collaboration with ViiV Healthcare – a joint venture of GlaxoSmithKline (LSE: GSK), Pfizer (NYSE: PFE) and Shionogi (TYO: 4507) – to facilitate greater availability of critically needed medicines for children living with HIV.

There are 3.4 million children living with HIV worldwide. However, only 562,000 of them have access to medicines, according to the World Health Organization. Treating them with currently available drugs is challenging, as many are not adapted for use in children. Under the collaboration, one key pediatric HIV medicine recommended by the WHO, abacavir, can be supplied in the 118 countries where 98.7% of children living with HIV reside, under a patent licence.

Also agree to allow further low-cost versions

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK